HSP70 Interactome‐Mediated Proteolysis Targeting Chimera (HSP70‐PROTAC) for Ferroptosis‐Driven Cancer Treatment
Advanced Science · 2026
DOI: 10.1002/advs.202513655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Jinyun Dong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. Hauptthemen laut MEDLINE: Ferroptosis, HSP70 Heat-Shock Proteins, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Pioneer" and "Leading Goose" R&D Program of Zhejiang, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Targeted protein degradation (TPD) represents a transformative therapeutic paradigm that harnesses the cellular degradation machinery to pharmacologically eliminate disease‐causing proteins with aberrant expression. This work here reports the first design of an HSP70 interactome‐mediated proteolysis targeting chimera (HSP70‐PROTAC) for the degradation of the intracellular therapeutically relevant proteins via dual processes of ubiquitin‐proteasomal degradation (UPS) and chaperone‐mediated autophagy (CMA). By hijacking the highly expressed heat shock cognate protein (Hsc70) isoform complex in tumor tissues to glutathione peroxidase 4 (GPX4) protein, this work successfully develops an HSP70‐PROTAC molecule GDAz‐3 that potently and rapidly eliminates GPX4 in HT1080 cells, thereby triggering ferroptosis with high selectivity. Correspondingly, GDAz‐3 exhibits a remarkable tumor‐inhibitory effect in the HT1080 xenograft tumor mouse model without obvious toxicity. In addition, this work demonstrates the versatility of HSP70‐based PROTACs by effectively degrading additional endogenous bromodomain‐containing protein 4 (BRD4) in cancer cells. More importantly, the degradation of GPX4 mediated by GDAz‐3 occurs with comparable efficiency in CRBN/VHL‐knockdown cells and 786‐O cells intrinsically lacking VHL expression, which facilitates expanding the application scope and overcoming drug resistance of traditional PROTAC. These findings suggest that HSP70‐PROTAC is a novel and feasible strategy for the future development of TPD technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Innovative Drug Research, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- Department of Pharmaceutical Sciences, Institute for Biotechnology, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
- MOE Frontier Science Centre for Precision Oncology, University of Macau, Macau, SAR, 999078, China.
- Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome, Zhejiang Chinese Medical University, China Collaborative Graduate School of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Jiang-Jiang Qin
Förderung
- "Pioneer" and "Leading Goose" R&D Program of Zhejiang
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Medical Science and Technology Project of Zhejiang Province
- Program of Zhejiang Provincial TCM Sci-Tech Plan
- Zhejiang Province Medical Science and Technology Project
- CACMS Innovation Fund
Zitieren
APA
Dong, J., Li, Y., Liang, H., Wu, Z., Wang, S., Wang, Y., Xu, J., Lan, Y., Cai, M., Pan, G., Yang, H., Miao, K., Chen, Z. S., Tao, F., Ma, X., & Qin, J. J. (2026). HSP70 Interactome‐Mediated Proteolysis Targeting Chimera (HSP70‐PROTAC) for Ferroptosis‐Driven Cancer Treatment. Advanced Science. https://doi.org/10.1002/advs.202513655
Vancouver
Dong J, Li Y, Liang H, Wu Z, Wang S, Wang Y, et al. HSP70 Interactome‐Mediated Proteolysis Targeting Chimera (HSP70‐PROTAC) for Ferroptosis‐Driven Cancer Treatment. Advanced Science. 2026. doi:10.1002/advs.202513655
BibTeX
@article{Dong2026,
author = {Dong, Jinyun and Li, Yulong and Liang, Hui and Wu, Zumei and Wang, Shiqun and Wang, Yichao and Xu, Jieyu and Lan, Yanning and Cai, Maohua and Pan, Guangzhao and Yang, Haiyan and Miao, Kai and Chen, Zhe-Sheng and Tao, Fangfang and Ma, Xuelei and Qin, Jiang-Jiang},
title = {HSP70 Interactome‐Mediated Proteolysis Targeting Chimera (HSP70‐PROTAC) for Ferroptosis‐Driven Cancer Treatment},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202513655}
}
EUVIMED